Document is current
Any future updates will be listed below
-
Authors
Zhao, Ruiyue
Chen, Jinhua
Ye, Ting
Chu, Jianmin
Li, Jingwen
Zhang, Yan
Xu, Siran
Liu, Shaoyu
Chen, Ling
Ploessl, Karl
Alexoff, David
Kung, Hank F.
Zhu, Lin
Wang, Xinlu https://orcid.org/0000-0003-1997-5687
-
Funding
Funding for this research was provided by:
Guangdong Regional Joint Fund (2022A1515110941)
Basic and Applied Basic Research Foundation of Guangdong Province (2023A04J1196)
Guangzhou Basic and Applied Basic Research (2024A03J1228)
National Natural Science Foundation of China (82271267)
Key Realm R&D Program of Guangdong Province (2018B030337001)
- License Information
-
More Information
Article History
Received: 27 August 2024
Accepted: 1 October 2024
First Online: 16 October 2024
Declarations
:
: This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (ES-2021-62), and it was conducted according to the principles of the Declaration of Helsinki. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200057218, Registered 16 August 2021, .
: Informed consent was obtained from all participants included in the study.
: David Alexoff, Karl Ploessl, and Hank F. Kung are employees of Five Eleven Pharma Inc., and Hank Kung is also the founder and board of the company, which holds the patent rights for D6-[<sup>18</sup>F]FP-(+)-DTBZ and related technology. Other authors have no conflicts of interest or relevant financial activities to disclose.
